<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	
	xmlns:georss="http://www.georss.org/georss"
	xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#"
	>

<channel>
	<title>Biotechblog</title>
	<atom:link href="http://www.biotechblog.com/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.biotechblog.com</link>
	<description>Biotechnology business, policy, and more!</description>
	<lastBuildDate>Mon, 15 Jul 2024 13:44:00 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.5.5</generator>
<site xmlns="com-wordpress:feed-additions:1">38554639</site>	<item>
		<title>The Complexity Advantage: Why Advanced Delivery Methods Deter Generic Competition</title>
		<link>https://www.drugpatentwatch.com/blog/the-complexity-advantage-why-advanced-delivery-methods-deter-generic-competition/</link>
		
		<dc:creator><![CDATA[DrugPatentWatch]]></dc:creator>
		<pubDate>Mon, 15 Jul 2024 13:44:00 +0000</pubDate>
				<category><![CDATA[Insights]]></category>
		<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/?p=23521</guid>

					<description><![CDATA[The Strategic Advantage of Complex Drug Delivery Systems In the highly competitive pharmaceutical landscape, adopting complex drug delivery systems can […]
Source
<p><a href="https://www.drugpatentwatch.com/blog/the-complexity-advantage-why-advanced-delivery-methods-deter-generic-competition/">Source</a></p>]]></description>
		
		
		<enclosure url="" length="0" type="" />

		<post-id xmlns="com-wordpress:feed-additions:1">40815</post-id>	</item>
		<item>
		<title>Rx for Change: How Nonprofit Pharma is Reshaping the Industry</title>
		<link>https://www.drugpatentwatch.com/blog/rx-for-change-how-nonprofit-pharma-is-reshaping-the-industry/</link>
		
		<dc:creator><![CDATA[DrugPatentWatch]]></dc:creator>
		<pubDate>Mon, 15 Jul 2024 13:37:28 +0000</pubDate>
				<category><![CDATA[Insights]]></category>
		<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/?p=23961</guid>

					<description><![CDATA[An HHS report titled “The Potential Role of The Nonprofit Pharmaceutical Industry in Addressing Shortages and Increasing Access to Essential […]
Source
<p><a href="https://www.drugpatentwatch.com/blog/rx-for-change-how-nonprofit-pharma-is-reshaping-the-industry/">Source</a></p>]]></description>
		
		
		<enclosure url="" length="0" type="" />

		<post-id xmlns="com-wordpress:feed-additions:1">40817</post-id>	</item>
		<item>
		<title>New tentative approval for Alembic drug dabigatran etexilate mesylate</title>
		<link>https://www.drugpatentwatch.com/blog/new-tentative-approval-for-alembic-drug-dabigatran-etexilate-mesylate-24/</link>
		
		<dc:creator><![CDATA[DrugPatentWatch – Make Better Decisions]]></dc:creator>
		<pubDate>Mon, 15 Jul 2024 04:06:57 +0000</pubDate>
				<category><![CDATA[Tentative Approval]]></category>
		<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/new-tentative-approval-for-alembic-drug-dabigatran-etexilate-mesylate-24/</guid>

					<description><![CDATA[Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd […]
Source
<p><a href="https://www.drugpatentwatch.com/blog/new-tentative-approval-for-alembic-drug-dabigatran-etexilate-mesylate-24/">Source</a></p>]]></description>
		
		
		<enclosure url="" length="0" type="" />

		<post-id xmlns="com-wordpress:feed-additions:1">40809</post-id>	</item>
		<item>
		<title>Which pharmaceutical drugs have the most drug patents in Austria?</title>
		<link>https://www.drugpatentwatch.com/blog/which-pharmaceutical-drugs-have-the-most-drug-patents-in-austria-7/</link>
		
		<dc:creator><![CDATA[DrugPatentWatch – Make Better Decisions]]></dc:creator>
		<pubDate>Mon, 15 Jul 2024 04:06:55 +0000</pubDate>
				<category><![CDATA[Infographic]]></category>
		<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/which-pharmaceutical-drugs-have-the-most-drug-patents-in-austria-7/</guid>

					<description><![CDATA[This chart shows the drugs with the most patents in Austria. Patents must be filed in each country (or, in […]
Source
<p><a href="https://www.drugpatentwatch.com/blog/which-pharmaceutical-drugs-have-the-most-drug-patents-in-austria-7/">Source</a></p>]]></description>
		
		
		<enclosure url="" length="0" type="" />

		<post-id xmlns="com-wordpress:feed-additions:1">40810</post-id>	</item>
		<item>
		<title>New patent expiration for United Therap drug ORENITRAM</title>
		<link>https://www.drugpatentwatch.com/blog/new-patent-expiration-for-united-therap-drug-orenitram-2/</link>
		
		<dc:creator><![CDATA[DrugPatentWatch – Make Better Decisions]]></dc:creator>
		<pubDate>Sun, 14 Jul 2024 04:07:00 +0000</pubDate>
				<category><![CDATA[patent expiration]]></category>
		<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/new-patent-expiration-for-united-therap-drug-orenitram-2/</guid>

					<description><![CDATA[Annual Drug Patent Expirations for ORENITRAM Orenitram is a drug marketed by United Therap and is included in one NDA. […]
Source
<p><a href="https://www.drugpatentwatch.com/blog/new-patent-expiration-for-united-therap-drug-orenitram-2/">Source</a></p>]]></description>
		
		
		<enclosure url="" length="0" type="" />

		<post-id xmlns="com-wordpress:feed-additions:1">40796</post-id>	</item>
		<item>
		<title>New patent expiration for United Therap drug ORENITRAM</title>
		<link>https://www.drugpatentwatch.com/blog/new-patent-expiration-for-united-therap-drug-orenitram-2/</link>
		
		<dc:creator><![CDATA[DrugPatentWatch – Make Better Decisions]]></dc:creator>
		<pubDate>Sun, 14 Jul 2024 04:07:00 +0000</pubDate>
				<category><![CDATA[patent expiration]]></category>
		<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/new-patent-expiration-for-united-therap-drug-orenitram-2/</guid>

					<description><![CDATA[Annual Drug Patent Expirations for ORENITRAM Orenitram is a drug marketed by United Therap and is included in one NDA. […]
Source
<p><a href="https://www.drugpatentwatch.com/blog/new-patent-expiration-for-united-therap-drug-orenitram-2/">Source</a></p>]]></description>
		
		
		<enclosure url="" length="0" type="" />

		<post-id xmlns="com-wordpress:feed-additions:1">40795</post-id>	</item>
		<item>
		<title>New tentative approval for Alembic drug dabigatran etexilate mesylate</title>
		<link>https://www.biotechblog.com/new-tentative-approval-for-alembic-drug-dabigatran-etexilate-mesylate-23/</link>
		
		<dc:creator><![CDATA[DrugPatentWatch – Make Better Decisions]]></dc:creator>
		<pubDate>Sun, 14 Jul 2024 04:07:00 +0000</pubDate>
				<category><![CDATA[General Biotechnology]]></category>
		<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/new-tentative-approval-for-alembic-drug-dabigatran-etexilate-mesylate-23/</guid>

					<description><![CDATA[Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd […]
Source
<p><a href="https://www.biotechblog.com/new-tentative-approval-for-alembic-drug-dabigatran-etexilate-mesylate-23/">Source</a></p>]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">40792</post-id>	</item>
		<item>
		<title>Which pharmaceutical companies have the most SPCs in Ireland?</title>
		<link>https://www.drugpatentwatch.com/blog/which-pharmaceutical-companies-have-the-most-spcs-in-ireland-16/</link>
		
		<dc:creator><![CDATA[DrugPatentWatch – Make Better Decisions]]></dc:creator>
		<pubDate>Sun, 14 Jul 2024 04:06:59 +0000</pubDate>
				<category><![CDATA[Infographic]]></category>
		<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/which-pharmaceutical-companies-have-the-most-spcs-in-ireland-16/</guid>

					<description><![CDATA[This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Ireland. SPCs are used in European […]
Source
<p><a href="https://www.drugpatentwatch.com/blog/which-pharmaceutical-companies-have-the-most-spcs-in-ireland-16/">Source</a></p>]]></description>
		
		
		<enclosure url="" length="0" type="" />

		<post-id xmlns="com-wordpress:feed-additions:1">40800</post-id>	</item>
		<item>
		<title>Which pharmaceutical companies have the most SPCs in Ireland?</title>
		<link>https://www.drugpatentwatch.com/blog/which-pharmaceutical-companies-have-the-most-spcs-in-ireland-16/</link>
		
		<dc:creator><![CDATA[DrugPatentWatch – Make Better Decisions]]></dc:creator>
		<pubDate>Sun, 14 Jul 2024 04:06:59 +0000</pubDate>
				<category><![CDATA[Infographic]]></category>
		<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/which-pharmaceutical-companies-have-the-most-spcs-in-ireland-16/</guid>

					<description><![CDATA[This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Ireland. SPCs are used in European […]
Source
<p><a href="https://www.drugpatentwatch.com/blog/which-pharmaceutical-companies-have-the-most-spcs-in-ireland-16/">Source</a></p>]]></description>
		
		
		<enclosure url="" length="0" type="" />

		<post-id xmlns="com-wordpress:feed-additions:1">40799</post-id>	</item>
		<item>
		<title>New tentative approval for Alembic drug dabigatran etexilate mesylate</title>
		<link>https://www.drugpatentwatch.com/blog/new-tentative-approval-for-alembic-drug-dabigatran-etexilate-mesylate-22/</link>
		
		<dc:creator><![CDATA[DrugPatentWatch – Make Better Decisions]]></dc:creator>
		<pubDate>Sat, 13 Jul 2024 04:09:21 +0000</pubDate>
				<category><![CDATA[Tentative Approval]]></category>
		<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/new-tentative-approval-for-alembic-drug-dabigatran-etexilate-mesylate-22/</guid>

					<description><![CDATA[Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd […]
Source
<p><a href="https://www.drugpatentwatch.com/blog/new-tentative-approval-for-alembic-drug-dabigatran-etexilate-mesylate-22/">Source</a></p>]]></description>
		
		
		<enclosure url="" length="0" type="" />

		<post-id xmlns="com-wordpress:feed-additions:1">40780</post-id>	</item>
		<item>
		<title>Which pharmaceutical drugs have the most drug patents in United Kingdom?</title>
		<link>https://www.drugpatentwatch.com/blog/which-pharmaceutical-drugs-have-the-most-drug-patents-in-united-kingdom-5/</link>
		
		<dc:creator><![CDATA[DrugPatentWatch – Make Better Decisions]]></dc:creator>
		<pubDate>Sat, 13 Jul 2024 04:09:20 +0000</pubDate>
				<category><![CDATA[Infographic]]></category>
		<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/which-pharmaceutical-drugs-have-the-most-drug-patents-in-united-kingdom-5/</guid>

					<description><![CDATA[This chart shows the drugs with the most patents in United Kingdom. Patents must be filed in each country (or, […]
Source
<p><a href="https://www.drugpatentwatch.com/blog/which-pharmaceutical-drugs-have-the-most-drug-patents-in-united-kingdom-5/">Source</a></p>]]></description>
		
		
		<enclosure url="" length="0" type="" />

		<post-id xmlns="com-wordpress:feed-additions:1">40782</post-id>	</item>
		<item>
		<title>Excipient Use in Biopharmaceuticals: Key Insights</title>
		<link>https://chemintel360.com/excipient-use-in-biopharmaceuticals-key-insights/</link>
		
		<dc:creator><![CDATA[ChemIntel360]]></dc:creator>
		<pubDate>Fri, 12 Jul 2024 15:16:00 +0000</pubDate>
				<category><![CDATA[Resources]]></category>
		<guid isPermaLink="false">https://chemintel360.com/?p=1613</guid>

					<description><![CDATA[The biopharmaceutical industry has witnessed significant advancements over the past few decades, with excipients playing a crucial role in the formulation and stability of therapeutic drugs. Excipients, often considered the unsung heroes of drug develo...
<p><a href="https://chemintel360.com/excipient-use-in-biopharmaceuticals-key-insights/">Source</a></p>]]></description>
		
		
		<enclosure url="" length="0" type="" />

		<post-id xmlns="com-wordpress:feed-additions:1">40775</post-id>	</item>
		<item>
		<title>New patent for Bristol drug AUGTYRO</title>
		<link>https://www.drugpatentwatch.com/blog/new-patent-for-bristol-drug-augtyro-2/</link>
		
		<dc:creator><![CDATA[DrugPatentWatch – Make Better Decisions]]></dc:creator>
		<pubDate>Fri, 12 Jul 2024 04:06:58 +0000</pubDate>
				<category><![CDATA[Patent Added]]></category>
		<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/new-patent-for-bristol-drug-augtyro-2/</guid>

					<description><![CDATA[Annual Drug Patent Expirations for AUGTYRO Augtyro is a drug marketed by Bristol and is included in one NDA. It […]
Source
<p><a href="https://www.drugpatentwatch.com/blog/new-patent-for-bristol-drug-augtyro-2/">Source</a></p>]]></description>
		
		
		<enclosure url="" length="0" type="" />

		<post-id xmlns="com-wordpress:feed-additions:1">40768</post-id>	</item>
		<item>
		<title>New patent for Vanda Pharms drug HETLIOZ LQ</title>
		<link>https://www.drugpatentwatch.com/blog/new-patent-for-vanda-pharms-drug-hetlioz-lq-12/</link>
		
		<dc:creator><![CDATA[DrugPatentWatch – Make Better Decisions]]></dc:creator>
		<pubDate>Fri, 12 Jul 2024 04:06:58 +0000</pubDate>
				<category><![CDATA[Patent Added]]></category>
		<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/new-patent-for-vanda-pharms-drug-hetlioz-lq-12/</guid>

					<description><![CDATA[Annual Drug Patent Expirations for HETLIOZ+LQ Hetlioz Lq is a drug marketed by Vanda Pharms Inc and is included in […]
Source
<p><a href="https://www.drugpatentwatch.com/blog/new-patent-for-vanda-pharms-drug-hetlioz-lq-12/">Source</a></p>]]></description>
		
		
		<enclosure url="" length="0" type="" />

		<post-id xmlns="com-wordpress:feed-additions:1">40766</post-id>	</item>
		<item>
		<title>New patent for Arcutis drug ZORYVE</title>
		<link>https://www.drugpatentwatch.com/blog/new-patent-for-arcutis-drug-zoryve-7/</link>
		
		<dc:creator><![CDATA[DrugPatentWatch – Make Better Decisions]]></dc:creator>
		<pubDate>Fri, 12 Jul 2024 04:06:58 +0000</pubDate>
				<category><![CDATA[Patent Added]]></category>
		<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/new-patent-for-arcutis-drug-zoryve-7/</guid>

					<description><![CDATA[Annual Drug Patent Expirations for ZORYVE Zoryve is a drug marketed by Arcutis and is included in two NDAs. It […]
Source
<p><a href="https://www.drugpatentwatch.com/blog/new-patent-for-arcutis-drug-zoryve-7/">Source</a></p>]]></description>
		
		
		<enclosure url="" length="0" type="" />

		<post-id xmlns="com-wordpress:feed-additions:1">40764</post-id>	</item>
		<item>
		<title>New patent for Vanda Pharms drug HETLIOZ</title>
		<link>https://www.drugpatentwatch.com/blog/new-patent-for-vanda-pharms-drug-hetlioz-15/</link>
		
		<dc:creator><![CDATA[DrugPatentWatch – Make Better Decisions]]></dc:creator>
		<pubDate>Fri, 12 Jul 2024 04:06:58 +0000</pubDate>
				<category><![CDATA[Patent Added]]></category>
		<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/new-patent-for-vanda-pharms-drug-hetlioz-15/</guid>

					<description><![CDATA[Annual Drug Patent Expirations for HETLIOZ Hetlioz is a drug marketed by Vanda Pharms Inc and is included in two […]
Source
<p><a href="https://www.drugpatentwatch.com/blog/new-patent-for-vanda-pharms-drug-hetlioz-15/">Source</a></p>]]></description>
		
		
		<enclosure url="" length="0" type="" />

		<post-id xmlns="com-wordpress:feed-additions:1">40762</post-id>	</item>
		<item>
		<title>New tentative approval for Alembic drug dabigatran etexilate mesylate</title>
		<link>https://www.drugpatentwatch.com/blog/new-tentative-approval-for-alembic-drug-dabigatran-etexilate-mesylate-21/</link>
		
		<dc:creator><![CDATA[DrugPatentWatch – Make Better Decisions]]></dc:creator>
		<pubDate>Fri, 12 Jul 2024 04:06:57 +0000</pubDate>
				<category><![CDATA[Tentative Approval]]></category>
		<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/new-tentative-approval-for-alembic-drug-dabigatran-etexilate-mesylate-21/</guid>

					<description><![CDATA[Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd […]
Source
<p><a href="https://www.drugpatentwatch.com/blog/new-tentative-approval-for-alembic-drug-dabigatran-etexilate-mesylate-21/">Source</a></p>]]></description>
		
		
		<enclosure url="" length="0" type="" />

		<post-id xmlns="com-wordpress:feed-additions:1">40770</post-id>	</item>
		<item>
		<title>Which pharmaceutical companies have the most drug patents in Sweden?</title>
		<link>https://www.drugpatentwatch.com/blog/which-pharmaceutical-companies-have-the-most-drug-patents-in-sweden-14/</link>
		
		<dc:creator><![CDATA[DrugPatentWatch – Make Better Decisions]]></dc:creator>
		<pubDate>Fri, 12 Jul 2024 04:06:56 +0000</pubDate>
				<category><![CDATA[Infographic]]></category>
		<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/which-pharmaceutical-companies-have-the-most-drug-patents-in-sweden-14/</guid>

					<description><![CDATA[This chart shows the pharmaceutical companies with the most patents in Sweden. Patents must be filed in each country (or, […]
Source
<p><a href="https://www.drugpatentwatch.com/blog/which-pharmaceutical-companies-have-the-most-drug-patents-in-sweden-14/">Source</a></p>]]></description>
		
		
		<enclosure url="" length="0" type="" />

		<post-id xmlns="com-wordpress:feed-additions:1">40772</post-id>	</item>
		<item>
		<title>CDMO Value Proposition: Why It Matters</title>
		<link>https://www.drugpatentwatch.com/blog/cdmo-value-proposition-why-it-matters/</link>
		
		<dc:creator><![CDATA[DrugPatentWatch]]></dc:creator>
		<pubDate>Thu, 11 Jul 2024 19:42:09 +0000</pubDate>
				<category><![CDATA[Insights]]></category>
		<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/?p=23743</guid>

					<description><![CDATA[The value proposition of Contract Development and Manufacturing Organizations (CDMOs) has become increasingly crucial in the pharmaceutical industry. As the […]
Source
<p><a href="https://www.drugpatentwatch.com/blog/cdmo-value-proposition-why-it-matters/">Source</a></p>]]></description>
		
		
		<enclosure url="" length="0" type="" />

		<post-id xmlns="com-wordpress:feed-additions:1">40759</post-id>	</item>
		<item>
		<title>How to Improve Drug Stability with Excipients</title>
		<link>https://chemintel360.com/how-to-improve-drug-stability-with-excipients/</link>
		
		<dc:creator><![CDATA[ChemIntel360]]></dc:creator>
		<pubDate>Thu, 11 Jul 2024 14:56:00 +0000</pubDate>
				<category><![CDATA[Resources]]></category>
		<guid isPermaLink="false">https://chemintel360.com/?p=1610</guid>

					<description><![CDATA[In the pharmaceutical industry, ensuring the stability of drug products is paramount. Drug stability refers to the ability of a pharmaceutical product to maintain its physical, chemical, therapeutic, and microbiological properties throughout its shelf ...
<p><a href="https://chemintel360.com/how-to-improve-drug-stability-with-excipients/">Source</a></p>]]></description>
		
		
		<enclosure url="" length="0" type="" />

		<post-id xmlns="com-wordpress:feed-additions:1">40752</post-id>	</item>
	</channel>
</rss>
